Search Results - Therapeutics

5 Results Sort By:
Trans-buccal naloxone for non-specialist emergency opiate overdose reversal
IntroductionNaloxone is a drug that is used to block the effects of opioids, particularly in overdose. It is typically administered to patients by intramuscular or subcutaneous injection. Whilst first responders may be familiar with this practice, family members and/or friends of the patient may find it difficult. The FDA has approved a hand-held a...
Published: 09/08/2017   |   Inventor(s): John Strang, Benjamin Forbes, Paul Royall, Rebecca McDonald, David Taylor, Abdulmalik Alqurshi
Category(s): Therapeutics
Nanoparticles suitable for multiple imaging modalities
ProblemMedical imaging plays an increasingly important role not only in disease diagnosis but also in monitoring the therapeutic treatment. The principal medical imaging modalities include magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission commuted tomography (SPECT), and optical imaging (OI). However, ea...
Published: 13/06/2017   |   Inventor(s): Xianjin Cui, Mark Green, Philip Blower
Category(s): Diagnostics, Therapeutics, Research Tools - Imaging
Candidalysin: Anti-fungal target and immunotherapeutic candidate
The Problem Candida albicans is an opportunistic fungal pathogen, which normally exists as a commensal of the oral cavity and gastrointestinal tracts and frequently causes of superficial vaginitis infections. Moreover, common clinical procedures, such as gastrointestinal surgery, implantation of a central venous catheter or ant...
Published: 04/07/2014   |   Inventor(s): Julian Naglik, Bernhard Hube, David Moyes, Sarah Höfs, Duncan Wilson, Shirley Tang, Jonathan Richardson
Category(s): Diagnostics, Therapeutics
Targeting acute myeloid leukaemia with Poly-ADP-ribose polymerase (PARP) inhibitors.
SummaryAcute myeloid leukemia (AML) is one of the most common cancers, accounting for about 30,000 new cases each year in the US and EU. Despite recent advances in leukemia research, AML patients are still receiving the same treatment utilised over past few decades, and have a relatively poor prognosis, with 5 year overall survival rate of only abo...
Published: 08/05/2014   |   Inventor(s): Eric So, Maria Teresa Esposito
Category(s): Therapeutics
Anti-CSPG4 antibody for the treatment of melanoma
SummaryA chimeric IgE class anti-CSPG4 antibody has been developed which has demonstrated positive results in vitro and in vivo. The antibody is designed to target immune responses directly against melanoma tumour cells, circumventing the broad immune activatory properties of currently approved immunotherapies.Figure: CSPG4 IgE restricts growth of ...
Published: 09/05/2012   |   Inventor(s): Sophia Karagiannis, Frank Nestle, Andrew Beavil
Category(s): Therapeutics